A pediatric epilepsy diagnostic tool for use in resource-limited settings: A pilot study

Archana A Patel1, Ornella Ciccone2, Adrian Njau3

  • 1Boston Children's Hospital, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Harvard Medical School, Boston, MA, United States.

Insights

A new questionnaire helps diagnose focal versus generalized epilepsy in children, improving accuracy in underserved regions. This tool aids primary healthcare providers in resource-limited settings, potentially guiding medication choices.

Area of Science:

  • Neurology
  • Global Health
  • Medical Diagnostics

Background:

  • Epilepsy affects 50 million globally, with 80% in resource-limited areas lacking specialist care.
  • Primary healthcare providers often manage epilepsy with limited training and diagnostic tools.

Purpose of the Study:

  • To develop and pilot a questionnaire to differentiate focal from generalized epilepsy in children.
  • To improve diagnostic accuracy for guiding epilepsy medication choices in resource-limited settings.

Main Methods:

  • A 15-item questionnaire was developed from literature and chart reviews, excluding simple motor seizures.
  • The questionnaire was translated and prospectively validated in Tanzania and Zambia with 59 children (6 months-18 years).
  • Caregiver responses were compared against a gold standard diagnosis by a pediatric neurologist, including EEG interpretation.

Main Results:

  • Of 43 eligible patients, 65% had focal epilepsy and 35% had generalized epilepsy.
  • The questionnaire demonstrated a sensitivity of 78% and a positive predictive value of 81.5%.
  • Statistical analysis confirmed the questionnaire's discriminative validity in classifying epilepsy types (p<0.001).

Conclusions:

  • The developed questionnaire offers a simple method to enhance diagnostic accuracy for pediatric epilepsy in resource-limited settings.
  • This tool can assist healthcare providers in bridging the diagnostic gap and potentially guiding treatment decisions.
  • Further validation in diverse settings is recommended to assess its impact on clinical practice and patient outcomes.
Abstract